Fujian Cosunter Pharmaceutical Intrinsic Value – Fujian Cosunter Pharmaceutical Awarded Drug Production License by Provincial Regulator in 2023.
March 19, 2023
Trending News ☀️
In 2023, Fujian Cosunter Pharmaceutical ($SZSE:300436) (300436) was awarded a Drug Production License by the Provincial Regulator. This license marks a significant milestone for the Chinese pharmaceutical company and demonstrates the high quality of its products. This license also provides the company with access to the necessary manufacturing facilities and equipment needed to produce medicines on a large scale.
Additionally, it indicates that the company has met the quality standards set forth by the provincial regulator for drug production. Fujian Cosunter Pharmaceutical’s license is a testament to its commitment to providing safe and effective drugs to its customers. By being granted this license, the company has demonstrated its ability to produce products that meet the highest standards of safety, efficacy, and quality. This license serves as a testament to the company’s ongoing commitment to providing safe and effective drugs to their customers.
This news had a positive effect on the stock’s performance for the day as it opened at CNY34.3 and closed at CNY34.7, representing a 1.7% increase from its prior closing price of CNY34.2. The company is now able to produce drugs, allowing it to become more competitive in the market and potentially generate higher profits in the near future. Live Quote…
About the Company
Below shows the total revenue, net income and net margin for Fujian Cosunter Pharmaceutical. More…
|Total Revenues||Net Income||Net Margin|
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Fujian Cosunter Pharmaceutical. More…
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Fujian Cosunter Pharmaceutical. More…
|Total Assets||Total Liabilities||Book Value Per Share|
Key Ratios Snapshot
Some of the financial key ratios for Fujian Cosunter Pharmaceutical are shown below. More…
|3Y Rev Growth||3Y Operating Profit Growth||Operating Margin|
Analysis – Fujian Cosunter Pharmaceutical Intrinsic Value
GoodWhale has conducted an analysis of FUJIAN COSUNTER PHARMACEUTICAL’s financials and determined that the intrinsic value of the company’s share is around CNY40.2. This value was calculated using GoodWhale’s proprietary Valuation Line, which considers a variety of factors such as the company’s current and projected earnings, cash flow, and market conditions. Despite its intrinsic value, FUJIAN COSUNTER PHARMACEUTICAL stock is currently trading at CNY34.7, representing a 13.7% discount to its intrinsic value. This suggests that the stock is currently undervalued and could be a good investment opportunity. More…
Fujian Cosunter Pharmaceutical Co Ltd faces stiff competition from some of the top pharmaceutical companies in China, including Henan Newland Pharmaceutical Co Ltd, Nanjing Well Pharmaceutical Group Co Ltd, and Shaanxi Kanghui Pharmaceutical Co Ltd. All of these companies are vying for a share of the market and are continually striving to improve their products and services to better serve their customers.
– Henan Newland Pharmaceutical Co Ltd ($SZSE:301277)
Henan Newland Pharmaceutical Co Ltd is a Chinese pharmaceutical company that specializes in research, development, and production of innovative medicines and health products. With a market cap of 3.86 billion as of 2023, the company has established itself as one of the leading companies in the industry. Moreover, the company has earned a respectable Return on Equity (ROE) of 23.02%, indicating its strong financial performance. This demonstrates that Henan Newland Pharmaceutical Co Ltd is a well-managed and financially sound company that is committed to delivering quality products and services to its customers.
– Nanjing Well Pharmaceutical Group Co Ltd ($SHSE:603351)
Nanjing Well Pharmaceutical Group Co Ltd is a large-scale comprehensive pharmaceutical enterprise. It was established in 2001 and is currently listed on the Shanghai Stock Exchange. The company has a current market cap of 3.16B as of 2023, which is indicative of its impressive market performance. In addition, Nanjing Well Pharmaceutical Group Co Ltd boasts an impressive Return on Equity (ROE) of 4.53%. This indicates that the company is generating a substantial amount of profit in comparison to the amount of shareholder equity that is invested into the company. The company primarily specializes in the research, development, and production of pharmaceutical products, medical devices, and health products.
– Shaanxi Kanghui Pharmaceutical Co Ltd ($SHSE:603139)
Shaanxi Kanghui Pharmaceutical Co Ltd is a Beijing-based pharmaceutical company that produces prescription drugs for the Chinese market. Its market capitalization is 1.81B as of 2023 and its Return on Equity (ROE) is 2.46%. The company is known for its focus on research and development in order to create innovative, cutting-edge products. It also has partnerships with international companies to expand its reach and provide better services to its customers. Shaanxi Kanghui Pharmaceutical Co Ltd has shown strong growth in recent years and has become a major player in the Chinese pharmaceutical industry.
Fujian Cosunter Pharmaceutical has recently been awarded a production license by the provincial regulator in 2023, marking an important milestone for the company. Investing in this company would be a smart move for investors looking for potential opportunities in the pharmaceutical industry. This license allows Fujian Cosunter Pharmaceutical to produce drugs that can be sold both domestically and internationally, leading to potential revenue growth in the years ahead.
Additionally, they can now enjoy tax incentives and subsidies from local authorities, which can further reduce operational costs and improve profitability. With the growing demand for pharmaceuticals in China, this company is poised to benefit from increased sales and improved margins. Investing in Fujian Cosunter Pharmaceutical would be an attractive option for investors due to its strong potential for growth.
Leave a Comment